Vaccination

A cohort analysis of Rhode Island data showed populations at high risk of SARS-CoV-2 exposure are at greater likelihood of reinfection, and would benefit even more greatly from vaccination.

Analysis of patient-reported outcomes last flu season show an approximate 10% increased risk of mild vaccination reactions when receiving both a COVID-19 booster and flu shot instead of a lone booster dose.

The latest EUA, for two-dose NVX-CoV2373, introduces a protein-based adjuvant vaccine to the COVID-19 prevention market.

There was also a greater likelihood of vaccine recommendation observed from pediatricians compared to other medical specialties.

The adverse event rate was 2.2% for patients with IBD following 1 dose of the vaccine.

There was an adequate response for pediatric patients on biologics to the H1N1 and H3N2 serotypes.

The guidelines replace risk-based reccomendations for adults between 19-59 years.

Males between 50-64 who have been vaccinated without erythema were at the highest risk of GBS.

Nearly all of the doctors polled recommended the pneumococcal vaccine for patients with cardiovascular disease aged 65 years and older.

As influenza A(H3N2) remains the most prevalent subtype in the US, investigators estimated the available flu shot is not significantly preventing positive cases.

A new study suggests even the phrasing of telemedicine notifications may make a difference in vaccine uptake.

An Israel cohort analysis suggests a "hybrid" of natural and vaccine-induced immunity is associated with the rare likelihood of SARS-CoV-2 reinfection.

New US county data suggest more general and family physicians per capita is positively linked to increased rates of full COVID-19 vaccination.

There was no differences in the incidence of all-cause neonatal hospitalization, post neonatal hospitalizations after birth, congenital anomalies, or infant mortality.

Immunomodulators, incomplete vaccination, and non-mRNA vaccination were associated with a higher risk of adverse events for patients with IBD.

New data show "nocebo responses" are frequent in COVID-19 vaccine studies—which may drive recipients' expectation of side effects.

More than 70% of parents of children with asthma said they in favor of the influenza vaccine during the COVID-19 pandemic.

The data shows booster shots offer particularly strong protection against the variant.

Investigators found about 70% of rheumatology patients had a good antibody response to the COVID-19 vaccines.

The recombinant vaccine resulted in higher rates of seroprotection in all subjects, particularly those 45 years and older.

The vaccine design reduces the amount of antigen required to produce an immune response.

Earlier today the FDA authorized booster doses for the Pfizer or Moderna vaccine for all adults.

An estimated 23% of healthcare personnel contract influenza annually.

The new indication makes the quadrivalent Seqirus flu shot available for every US-eligible patient age group.

Risky sexual behavior is the sole independent predictor of acute HDV.

The VRBPAC voted 16-2 against the booster dose because of unclear evidence regarding the need.

Hospitals that use the 3-dose vaccine would spend approximately 37% more on prophylaxis for hepatitis B.

Grade 3 injection site redness led to the predefined stopping rules for 10 patients in the clinical trials.

Investigators report that the small number of adverse events from the vaccine were successfully treated, with the remaining participants experiencing no allergic responses.

Though operating room-based injections are predominantly performed, investigators could not find sufficient data that confirmed it as the only safe injection site.